The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Hepatocellular Carcinoma Case Studies

Richard Finn, MD: Potential for Systemic Therapy

Richard Finn, MD
Published Online:Jun 18, 2015
Steve C is a 56-year-old Caucasian construction worker from Miami, Florida with a history of chronic hepatitis C virus (HCV) infection and alcohol abuse.

Unresectable Hepatocellular Carcinoma: case 2

This patient could be considered a candidate for systemic therapy based on BCLC staging. It sounds like he has a large tumor that is causing some problems with his activities of daily living. Patients with Barcelona stage C disease are those who have a decreased performance status, a symptomatic tumor, vascular invasion or extrahepatic spread. This patient has those characteristics, specifically, decreased performance status and symptomatic tumor. Additionally, the patient has had disease progression following a chemoembolization procedure, so he could be considered a candidate for systemic therapy.

CASE 2: Unresectable Hepatocellular Carcinoma

Steve C is a 56-year-old Caucasian construction worker from Miami, Florida with a history of chronic hepatitis C virus (HCV) infection and alcohol abuse.

In January of 2013 the patient was diagnosed with unresectable hepatocellular carcinoma, with an encapsulated, 7-cm tumor identified in the right lobe on Gadolinium-enhanced MRI
  • Multidisciplinary team recommended TACE because of patient’s ongoing alcohol use, and patient achieved a partial response (>30% decrease by RECIST criteria)
In April 2014, the patient returns for follow up
  • Patient’s lab values include:
    • AFP: 1100 ng/mL; AST 322 IU/L
    • ALT: 195 IU/L
    • Total bilirubin: 1.8 mg/dL
    • Platelets: 85,000
  • At his current workup, the patient is classified as Child Pugh Class A, with a MELD score of 13; ECOG PS is 1
  • MRI with gadolinium is consistent with disease progression, with encapsulated lesion in the right lobe measuring 9 cm, consistent with HCC
  • A third TACE procedure is recommended by the MDT
Following the TACE procedure, imaging results show 65% necrosis in the treated area with residual 1.5-cm nodules
Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.